NO311325B1 - Anvendelse av en kombinasjon av en kolesterolbiosynteseinhibitor og en <beta>-laktam-kolesterolabsorpsjonsinhibitor for fremstilling av et medikament;og farmasöytisk preparat inneholdende disse inhibitorer - Google Patents

Anvendelse av en kombinasjon av en kolesterolbiosynteseinhibitor og en <beta>-laktam-kolesterolabsorpsjonsinhibitor for fremstilling av et medikament;og farmasöytisk preparat inneholdende disse inhibitorer Download PDF

Info

Publication number: NO311325B1
Authority: NO; Norway
Prior art keywords: cholesterol; inhibitor; lactam; cholesterol absorption; alkoxy
Prior art date: 1992-12-23

Application number

NO19952529A

Other languages

English (en)

Norwegian (no)

Other versions

NO952529L (no

NO952529D0 (no

Inventor

Harry R Davis

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-23

Filing date

1995-06-23

Publication date

2001-11-19

1995-06-23 Application filed by Schering Corp filed Critical Schering Corp

1995-06-23 Publication of NO952529L publication Critical patent/NO952529L/no

1995-06-23 Publication of NO952529D0 publication Critical patent/NO952529D0/no

2001-11-19 Publication of NO311325B1 publication Critical patent/NO311325B1/no

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 144
229940122502 Cholesterol absorption inhibitor Drugs 0.000 title claims abstract description 23
229940079593 drug Drugs 0.000 title claims description 4
239000003814 drug Substances 0.000 title claims description 4
238000004519 manufacturing process Methods 0.000 title claims description 4
235000012000 cholesterol Nutrition 0.000 title abstract description 37
239000003112 inhibitor Substances 0.000 title abstract description 20
230000015572 biosynthetic process Effects 0.000 title abstract description 19
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
150000003952 β-lactams Chemical class 0.000 claims abstract description 24
201000001320 Atherosclerosis Diseases 0.000 claims abstract description 8
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 32
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 32
229960004844 lovastatin Drugs 0.000 claims description 31
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 31
230000009467 reduction Effects 0.000 claims description 19
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 16
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 16
239000003937 drug carrier Substances 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 5
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 4
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
229960002965 pravastatin Drugs 0.000 claims description 4
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 4
IMNTVVOUWFPRSB-JWQCQUIFSA-N sch-48461 Chemical group C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(OC)=CC=2)C(=O)[C@@H]1CCCC1=CC=CC=C1 IMNTVVOUWFPRSB-JWQCQUIFSA-N 0.000 claims description 4
229960002855 simvastatin Drugs 0.000 claims description 4
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 4
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 3
229960003765 fluvastatin Drugs 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
-1 3-phenyl-1-propenyl Chemical group 0.000 claims description 2
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
125000005336 allyloxy group Chemical group 0.000 claims description 2
229960005370 atorvastatin Drugs 0.000 claims description 2
125000004980 cyclopropylene group Chemical group 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
238000000034 method Methods 0.000 abstract description 8
229940126062 Compound A Drugs 0.000 description 24
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 24
235000005911 diet Nutrition 0.000 description 10
230000037213 diet Effects 0.000 description 10
241000283973 Oryctolagus cuniculus Species 0.000 description 9
241000282472 Canis lupus familiaris Species 0.000 description 7
241000282693 Cercopithecidae Species 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
241000699800 Cricetinae Species 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
108010007622 LDL Lipoproteins Proteins 0.000 description 5
102000007330 LDL Lipoproteins Human genes 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
108090001030 Lipoproteins Proteins 0.000 description 4
102000004895 Lipoproteins Human genes 0.000 description 4
108010062497 VLDL Lipoproteins Proteins 0.000 description 4
238000000540 analysis of variance Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000002285 corn oil Substances 0.000 description 4
235000005687 corn oil Nutrition 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000000936 intestine Anatomy 0.000 description 4
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 4
241000282560 Macaca mulatta Species 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000001906 cholesterol absorption Effects 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
235000013861 fat-free Nutrition 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
238000005303 weighing Methods 0.000 description 3
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
108010089254 Cholesterol oxidase Proteins 0.000 description 2
108010004103 Chylomicrons Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
210000000941 bile Anatomy 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
210000001842 enterocyte Anatomy 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000000871 hypocholesterolemic effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000033227 intestinal cholesterol absorption Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
102000005782 Squalene Monooxygenase Human genes 0.000 description 1
108020003891 Squalene monooxygenase Proteins 0.000 description 1
102000000019 Sterol Esterase Human genes 0.000 description 1
108010055297 Sterol Esterase Proteins 0.000 description 1
102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
235000021068 Western diet Nutrition 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
229920000080 bile acid sequestrant Polymers 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000031154 cholesterol homeostasis Effects 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229940099246 mevacor Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
235000020925 non fasting Nutrition 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000000049 pigment Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000025505 regulation of cholesterol homeostasis Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
DFKDOZMCHOGOBR-UHFFFAOYSA-N zaragozic acid A Natural products O1C(C(O)(C(O2)C(O)=O)C(O)=O)(C(O)=O)C(OC(=O)C=CC(C)CC(C)CC)C(O)C21CCC(=C)C(OC(C)=O)C(C)CC1=CC=CC=C1 DFKDOZMCHOGOBR-UHFFFAOYSA-N 0.000 description 1
DFKDOZMCHOGOBR-NCSQYGPNSA-N zaragozic acid A Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CC[C@]12[C@H](O)[C@H]([C@](O2)(C(O)=O)[C@@](O)([C@H](O1)C(O)=O)C(O)=O)OC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)C1=CC=CC=C1 DFKDOZMCHOGOBR-NCSQYGPNSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)

NO19952529A 1992-12-23 1995-06-23 Anvendelse av en kombinasjon av en kolesterolbiosynteseinhibitor og en <beta>-laktam-kolesterolabsorpsjonsinhibitor for fremstilling av et medikament;og farmasöytisk preparat inneholdende disse inhibitorer NO311325B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US99548892A	1992-12-23	1992-12-23
PCT/US1993/012291 WO1994014433A1 (en)	1992-12-23	1993-12-21	COMBINATION OF A CHOLESTEROL BIOSYNTHESIS INHIBITOR AND A β-LACTAM CHOLESTEROL ABSORPTION INHIBITOR

Publications (3)

Publication Number	Publication Date
NO952529L NO952529L (no)	1995-06-23
NO952529D0 NO952529D0 (no)	1995-06-23
NO311325B1 true NO311325B1 (no)	2001-11-19

Family

ID=25541876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19952529A NO311325B1 (no)	1992-12-23	1995-06-23	Anvendelse av en kombinasjon av en kolesterolbiosynteseinhibitor og en <beta>-laktam-kolesterolabsorpsjonsinhibitor for fremstilling av et medikament;og farmasöytisk preparat inneholdende disse inhibitorer

Country Status (32)

Country	Link
US (1)	US5661145A (xx)
EP (1)	EP0675714B1 (xx)
JP (1)	JP3992728B2 (xx)
KR (1)	KR100306936B1 (xx)
CN (1)	CN1090479C (xx)
AT (1)	ATE175872T1 (xx)
AU (1)	AU680864B2 (xx)
CA (1)	CA2152351C (xx)
CZ (1)	CZ287125B6 (xx)
DE (1)	DE69323213T2 (xx)
DK (1)	DK0675714T3 (xx)
EE (1)	EE03383B1 (xx)
ES (1)	ES2128552T3 (xx)
FI (1)	FI952916A (xx)
GR (1)	GR3029405T3 (xx)
HR (1)	HRP931515B1 (xx)
HU (1)	HU221724B1 (xx)
IL (1)	IL108112A (xx)
LT (1)	LT3300B (xx)
LV (1)	LV10919B (xx)
MX (1)	MX9308053A (xx)
MY (1)	MY109538A (xx)
NO (1)	NO311325B1 (xx)
NZ (1)	NZ259790A (xx)
PL (1)	PL174128B1 (xx)
SG (1)	SG45147A1 (xx)
SI (1)	SI9300677A (xx)
SK (1)	SK281173B6 (xx)
TW (1)	TW319698B (xx)
WO (1)	WO1994014433A1 (xx)
YU (1)	YU49060B (xx)
ZA (1)	ZA939552B (xx)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996009827A2 (en) *	1994-09-20	1996-04-04	Pfizer Inc.	Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5624920A (en) *	1994-11-18	1997-04-29	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) *	1994-11-18	1997-05-27	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) *	1994-12-21	1997-08-12	Schering Corporation	4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
EA000514B1 (ru)	1995-11-02	1999-10-28	Варнер-Ламберт Компани	Способ нормализации липопротеидного профиля плазмы крови у млекопитающего и фармацевтическая композиция для его осуществления
US20030153541A1 (en) *	1997-10-31	2003-08-14	Robert Dudley	Novel anticholesterol compositions and method for using same
SI20109A (sl) *	1998-12-16	2000-06-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Stabilna farmacevtska formulacija
AR023463A1 (es) *	1999-04-16	2002-09-04	Schering Corp	Uso de compuestos de azetidinona
JP4945876B2 (ja) *	2000-04-05	2012-06-06	東レ株式会社	ハイモビリティーグループタンパクの吸着材および体液浄化カラム
US6979462B1 (en) *	2000-10-03	2005-12-27	Mutual Pharmaceutical Co., Inc.	Stabilization of solid drug formulations
US6584357B1 (en) *	2000-10-17	2003-06-24	Sony Corporation	Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (en)	2001-01-26	2011-11-30	Schering Corporation	Compositions comprising a sterol absorption inhibitor
CN101297969B (zh) *	2001-01-26	2011-03-09	先灵公司	过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
IL157552A0 (en)	2001-03-28	2004-03-28	Schering Corp	Enantioselective synthesis of azetidinone intermediate compounds
MXPA04002572A (es) *	2001-09-21	2004-05-31	Schering Corp	Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
WO2003026643A2 (en) *	2001-09-21	2003-04-03	Schering Corporation	Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US6984645B2 (en)	2001-11-16	2006-01-10	Bristol-Myers Squibb Company	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030204096A1 (en) *	2002-03-25	2003-10-30	Schering Corporation	Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en)	2002-07-05	2002-08-14	Astrazeneca Ab	Chemical compounds
US7135556B2 (en) *	2002-07-19	2006-11-14	Schering Corporation	NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es)	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ES2350977T3 (es)	2002-11-05	2011-01-28	Glaxo Group Limited	Agentes antibacterianos.
MXPA05009503A (es)	2003-03-07	2005-10-18	Schering Corp	Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
DE602004018617D1 (de)	2003-03-07	2009-02-05	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
EP1606287B1 (en) *	2003-03-07	2013-10-02	Merck Sharp & Dohme Corp.	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP1810971B1 (en) *	2003-03-07	2013-12-25	Merck Sharp & Dohme Corp.	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2005015434A (ja) *	2003-06-27	2005-01-20	Kotobuki Seiyaku Kk	血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20060089374A1 (en) *	2003-07-17	2006-04-27	Glenn Cornett	Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20050113314A1 (en) *	2003-08-29	2005-05-26	Fong Benson M.	Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US7371759B2 (en)	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
EP1918000A2 (en)	2003-11-05	2008-05-07	Schering Corporation	Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7420059B2 (en)	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
JP2007516287A (ja) *	2003-12-23	2007-06-21	メルク　エンド　カムパニー　インコーポレーテッド	抗高コレステロール血症化合物
CA2550215A1 (en)	2003-12-23	2005-07-07	Astrazeneca Ab	Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) *	2003-12-23	2004-01-28	Astrazeneca Ab	Chemical compounds
CA2553769C (en) *	2004-01-16	2011-01-04	Merck & Co., Inc.	Npc1l1 (npc3) and methods of identifying ligands thereof
CN101006074B (zh) *	2004-07-01	2012-02-15	欧科生医股份有限公司	作为nk1拮抗剂的哌啶衍生物
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060046996A1 (en)	2004-08-31	2006-03-02	Kowa Co., Ltd.	Method for treating hyperlipidemia
US20060154959A1 (en) *	2005-01-13	2006-07-13	Navitas Pharma	Combination therapies of cicletanine and carvedilol
JP2008514718A (ja) *	2004-09-29	2008-05-08	シェーリングコーポレイション	置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
US7517991B2 (en)	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076598A2 (en)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Thiazolopyridines as cannabinoid receptor modulators
WO2006076597A1 (en)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
US20080096915A1 (en) *	2005-01-13	2008-04-24	Greenberg Traurig LLP	Compositions for the treatment of metabolic disorders
US20070141174A1 (en) *	2005-01-13	2007-06-21	Navitas Pharma, Inc.	Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20060160850A1 (en)	2005-01-18	2006-07-20	Chongqing Sun	Bicyclic heterocycles as cannabinoid receptor modulators
DE602006004964D1 (de)	2005-02-10	2009-03-12	Bristol Myers Squibb Co	Dihydrochinazolinone als 5ht-modulatoren
US7629342B2 (en)	2005-06-17	2009-12-08	Bristol-Myers Squibb Company	Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en)	2005-06-17	2008-01-08	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7572808B2 (en)	2005-06-17	2009-08-11	Bristol-Myers Squibb Company	Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en)	2005-06-17	2008-11-18	Bristol-Myers Squibb Company	Triazolopyrimidine cannabinoid receptor 1 antagonists
UY29607A1 (es) *	2005-06-20	2007-01-31	Astrazeneca Ab	Compuestos quimicos
JP2008546784A (ja) *	2005-06-20	2008-12-25	シェーリングコーポレイション	ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
AR054482A1 (es) *	2005-06-22	2007-06-27	Astrazeneca Ab	Derivados de azetidinona para el tratamiento de hiperlipidemias
MY148538A (en) *	2005-06-22	2013-04-30	Astrazeneca Ab	Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR057383A1 (es) *	2005-06-22	2007-12-05	Astrazeneca Ab	Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar)	2005-06-22	2010-03-29	استرازينيكا ايه بي	مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057380A1 (es) *	2005-06-22	2007-11-28	Astrazeneca Ab	Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
US7795436B2 (en)	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es)	2005-10-26	2007-09-19	Bristol Myers Squibb Co	Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US20070105817A1 (en) *	2005-11-09	2007-05-10	Jim Page	Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
WO2007075702A2 (en) *	2005-12-21	2007-07-05	Schering Corporation	Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
US7553836B2 (en)	2006-02-06	2009-06-30	Bristol-Myers Squibb Company	Melanin concentrating hormone receptor-1 antagonists
WO2007100807A2 (en)	2006-02-24	2007-09-07	Schering Corporation	Npc1l1 orthologues
TW200811098A (en)	2006-04-27	2008-03-01	Astrazeneca Ab	Chemical compounds
US20070275052A1 (en) *	2006-05-24	2007-11-29	Glenmark Pharmaceuticals Limited	Pharmaceutical compositions containing sterol inhibitors
US20080103122A1 (en) *	2006-09-05	2008-05-01	Schering Corporation	Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080312241A1 (en) *	2007-01-03	2008-12-18	Gilead Sciences, Inc.	Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders
US20090011994A1 (en)	2007-07-06	2009-01-08	Bristol-Myers Squibb Company	Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010021681A2 (en) *	2008-08-18	2010-02-25	Combinatorx (Singapore) Pte. Ltd.	Compositions and methods for treatment of viral diseases
EP2411005A1 (en)	2009-03-27	2012-02-01	Bristol-Myers Squibb Company	Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
EP2892897A1 (en)	2012-09-05	2015-07-15	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en)	2012-09-05	2016-06-29	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
KR20210034039A (ko)	2018-07-19	2021-03-29	아스트라제네카 아베	다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물
IL308122A (en)	2021-06-16	2023-12-01	Celgene Corp	Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4680391A (en) *	1983-12-01	1987-07-14	Merck & Co., Inc.	Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4983597A (en) *	1989-08-31	1991-01-08	Merck & Co., Inc.	Beta-lactams as anticholesterolemic agents
US5120729A (en) *	1990-06-20	1992-06-09	Merck & Co., Inc.	Beta-lactams as antihypercholesterolemics
US5085473A (en) *	1990-10-09	1992-02-04	Yuhe Yang	Air actuated car curtain device
TW223059B (xx) *	1991-07-23	1994-05-01	Schering Corp
ES2613245T3 (es)	2012-01-26	2017-05-23	Intralot S.A. - Integrated Lottery Systems And Services	Métodos y sistemas para dispensar

1993
- 1993-12-03 LT LTIP1514A patent/LT3300B/lt not_active IP Right Cessation
- 1993-12-13 MX MX9308053A patent/MX9308053A/es unknown
- 1993-12-21 EP EP94904854A patent/EP0675714B1/en not_active Expired - Lifetime
- 1993-12-21 AT AT94904854T patent/ATE175872T1/de active
- 1993-12-21 CA CA002152351A patent/CA2152351C/en not_active Expired - Fee Related
- 1993-12-21 KR KR1019950702608A patent/KR100306936B1/ko not_active IP Right Cessation
- 1993-12-21 AU AU58720/94A patent/AU680864B2/en not_active Ceased
- 1993-12-21 DK DK94904854T patent/DK0675714T3/da active
- 1993-12-21 IL IL10811293A patent/IL108112A/en not_active IP Right Cessation
- 1993-12-21 NZ NZ259790A patent/NZ259790A/en not_active IP Right Cessation
- 1993-12-21 TW TW082110824A patent/TW319698B/zh not_active IP Right Cessation
- 1993-12-21 SK SK783-95A patent/SK281173B6/sk not_active IP Right Cessation
- 1993-12-21 WO PCT/US1993/012291 patent/WO1994014433A1/en active IP Right Grant
- 1993-12-21 PL PL93309636A patent/PL174128B1/pl not_active IP Right Cessation
- 1993-12-21 ES ES94904854T patent/ES2128552T3/es not_active Expired - Lifetime
- 1993-12-21 DE DE69323213T patent/DE69323213T2/de not_active Expired - Lifetime
- 1993-12-21 YU YU80293A patent/YU49060B/sh unknown
- 1993-12-21 CZ CZ19951643A patent/CZ287125B6/cs not_active IP Right Cessation
- 1993-12-21 MY MYPI93002792A patent/MY109538A/en unknown
- 1993-12-21 HU HU9501854A patent/HU221724B1/hu not_active IP Right Cessation
- 1993-12-21 ZA ZA939552A patent/ZA939552B/xx unknown
- 1993-12-21 US US08/454,348 patent/US5661145A/en not_active Expired - Lifetime
- 1993-12-21 SG SG1996000543A patent/SG45147A1/en unknown
- 1993-12-21 JP JP51530594A patent/JP3992728B2/ja not_active Expired - Fee Related
- 1993-12-22 SI SI9300677A patent/SI9300677A/sl not_active IP Right Cessation
- 1993-12-22 HR HR07/995,488A patent/HRP931515B1/xx not_active IP Right Cessation
- 1993-12-22 CN CN93112663A patent/CN1090479C/zh not_active Expired - Fee Related
1994
- 1994-11-23 EE EE9400341A patent/EE03383B1/xx not_active IP Right Cessation
1995
- 1995-06-14 FI FI952916A patent/FI952916A/fi unknown
- 1995-06-22 LV LVP-95-189A patent/LV10919B/en unknown
- 1995-06-23 NO NO19952529A patent/NO311325B1/no not_active IP Right Cessation
1999
- 1999-02-16 GR GR990400487T patent/GR3029405T3/el unknown

Also Published As

Publication number	Publication date
IL108112A0 (en)	1994-04-12
CN1095591A (zh)	1994-11-30
AU5872094A (en)	1994-07-19
CN1090479C (zh)	2002-09-11
CZ287125B6 (en)	2000-09-13
CZ164395A3 (en)	1996-03-13
SK78395A3 (en)	1996-05-08
SK281173B6 (sk)	2000-12-11
WO1994014433A1 (en)	1994-07-07
PL309636A1 (en)	1995-10-30
HU9501854D0 (en)	1995-08-28
CA2152351C (en)	2009-09-22
JP3992728B2 (ja)	2007-10-17
SG45147A1 (en)	1998-01-16
DK0675714T3 (da)	1999-09-13
HRP931515B1 (en)	2000-02-29
NZ259790A (en)	1997-02-24
LV10919B (en)	1996-04-20
LT3300B (en)	1995-06-26
EE03383B1 (et)	2001-04-16
EP0675714B1 (en)	1999-01-20
EP0675714A1 (en)	1995-10-11
HRP931515A2 (en)	1996-12-31
ZA939552B (en)	1994-10-12
YU80293A (sh)	1997-12-05
US5661145A (en)	1997-08-26
LTIP1514A (en)	1994-10-25
NO952529L (no)	1995-06-23
CA2152351A1 (en)	1994-07-07
FI952916A0 (fi)	1995-06-14
NO952529D0 (no)	1995-06-23
DE69323213D1 (de)	1999-03-04
KR100306936B1 (ko)	2001-11-30
MX9308053A (es)	1994-06-30
ATE175872T1 (de)	1999-02-15
YU49060B (sh)	2003-08-29
PL174128B1 (pl)	1998-06-30
HUT72081A (en)	1996-03-28
GR3029405T3 (en)	1999-05-28
JPH08505141A (ja)	1996-06-04
IL108112A (en)	1999-11-30
AU680864B2 (en)	1997-08-14
EE9400341A (et)	1996-04-15
ES2128552T3 (es)	1999-05-16
MY109538A (en)	1997-02-28
DE69323213T2 (de)	1999-07-08
HU221724B1 (hu)	2002-12-28
FI952916A (fi)	1995-06-14
TW319698B (xx)	1997-11-11
LV10919A (lv)	1995-12-20
SI9300677A (en)	1994-09-30

Publication	Publication Date	Title
NO311325B1 (no)	2001-11-19	Anvendelse av en kombinasjon av en kolesterolbiosynteseinhibitor og en <beta>-laktam-kolesterolabsorpsjonsinhibitor for fremstilling av et medikament;og farmasöytisk preparat inneholdende disse inhibitorer
EP1353696B1 (en)	2006-12-20	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
USH1286H (en)	1994-02-01	Method for treating peripheral atherosclerotic disease employing a cholesterol lowering drug, an ace inhibitor, or a combination thereof
US5593971A (en)	1997-01-14	Method for preventing onset of hypertension employing a cholesterol lowering drug
DE69121464T2 (de)	1997-03-27	Verfahren zur Verhütung, Stabilisierung oder Verursachung des Zurückgangs von Atherosklerose durch Anwendung einer Mischung von einem Cholesterol-vermindernden Arzneimittel mit einem ACE-Inhibitor
JP2001507363A (ja)	2001-06-05	イソプレノイド類とスタチン類との組合せによる腫瘍成長抑制方法
US4931430A (en)	1990-06-05	Method for preventing or treating anxiety employing an ACE inhibitor
NZ529243A (en)	2007-11-30	Use of polymethoxylated flavones for treating insulin resistance
US7012067B2 (en)	2006-03-14	Blood lipid ameliorant composition
US5989574A (en)	1999-11-23	Weight loss compound and method of using
EP0321221A2 (en)	1989-06-21	Method for preventing or treating anxiety employing an ace inhibitor
AU2001284657B2 (en)	2006-01-19	Use of vitamin d derivatives as bone resorption inhibitors
NZ299704A (en)	1997-06-24	Use of a beta-lactam cholesterol absorption inhibitor and a cholesterol biosynthesis inhibitor (eg lovastatin) in preparation of pharmaceutical compositions for treatment of plasma cholesterol levels
US6630502B2 (en)	2003-10-07	Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
JP2002249430A (ja)	2002-09-06	血中脂質改善剤組成物
GB2241890A (en)	1991-09-18	Preventing onset of or treating protein catabolism using an ace inhibitor
JP2002241281A (ja)	2002-08-28	血中脂質改善剤組成物

Legal Events

Date	Code	Title	Description
2012-07-23	MM1K	Lapsed by not paying the annual fees